TY - JOUR
T1 - Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
AU - UK ILD specialist centre collaboration
AU - Dixon, Giles
AU - Hague, Samuel
AU - Mulholland, Sarah
AU - Adamali, Huzaifa
AU - Khin, Aye Myat Noe
AU - Thould, Hannah
AU - Connon, Roisin
AU - Minnis, Paul
AU - Murtagh, Eoin
AU - Khan, Fasihul
AU - Toor, Sameen
AU - Lawrence, Alexandra
AU - Naqvi, Marium
AU - West, Alex
AU - Coker, Robina K
AU - Ward, Katie
AU - Yazbeck, Leda
AU - Hart, Simon
AU - Garfoot, Theresa
AU - Newman, Kate
AU - Rivera-Ortega, Pilar
AU - Stranks, Lachlan
AU - Beirne, Paul
AU - Bradley, Jessica
AU - Rowan, Catherine
AU - Wilson, Andrew M
AU - Jones, Mark G
AU - Rodrigues, Jonathan C L
AU - Tsaneva-Atanasova, Krasimira
AU - Barratt, Shaney L
AU - Chalmers, Jodie S
N1 - Publisher Copyright:
© The authors 2024.
PY - 2024/1
Y1 - 2024/1
N2 - BACKGROUND: Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in June 2021 and in England, Wales and Northern Ireland in November 2021. To date, there has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting.METHODS: 26 UK centres were invited to take part in a national service evaluation between 17 November 2021 and 30 September 2022. Summary data regarding underlying diagnosis, pulmonary function tests, diagnostic criteria, radiological appearance, concurrent immunosuppressive therapy and drug tolerability were collected via electronic survey.RESULTS: 24 UK prescribing centres responded to the service evaluation invitation. Between 17 November 2021 and 30 September 2022, 1120 patients received a multidisciplinary team recommendation to commence nintedanib for PF-ILD. The most common underlying diagnoses were hypersensitivity pneumonitis (298 out of 1120, 26.6%), connective tissue disease associated ILD (197 out of 1120, 17.6%), rheumatoid arthritis associated ILD (180 out of 1120, 16.0%), idiopathic nonspecific interstitial pneumonia (125 out of 1120, 11.1%) and unclassifiable ILD (100 out of 1120, 8.9%). Of these, 54.4% (609 out of 1120) were receiving concomitant corticosteroids, 355 (31.7%) out of 1120 were receiving concomitant mycophenolate mofetil and 340 (30.3%) out of 1120 were receiving another immunosuppressive/modulatory therapy. Radiological progression of ILD combined with worsening respiratory symptoms was the most common reason for the diagnosis of PF-ILD.CONCLUSION: We have demonstrated the use of nintedanib for the treatment of PF-ILD across a broad range of underlying conditions. Nintedanib is frequently co-prescribed alongside immunosuppressive and immunomodulatory therapy. The use of nintedanib for the treatment of PF-ILD has demonstrated acceptable tolerability in a real-world setting.
AB - BACKGROUND: Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in June 2021 and in England, Wales and Northern Ireland in November 2021. To date, there has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting.METHODS: 26 UK centres were invited to take part in a national service evaluation between 17 November 2021 and 30 September 2022. Summary data regarding underlying diagnosis, pulmonary function tests, diagnostic criteria, radiological appearance, concurrent immunosuppressive therapy and drug tolerability were collected via electronic survey.RESULTS: 24 UK prescribing centres responded to the service evaluation invitation. Between 17 November 2021 and 30 September 2022, 1120 patients received a multidisciplinary team recommendation to commence nintedanib for PF-ILD. The most common underlying diagnoses were hypersensitivity pneumonitis (298 out of 1120, 26.6%), connective tissue disease associated ILD (197 out of 1120, 17.6%), rheumatoid arthritis associated ILD (180 out of 1120, 16.0%), idiopathic nonspecific interstitial pneumonia (125 out of 1120, 11.1%) and unclassifiable ILD (100 out of 1120, 8.9%). Of these, 54.4% (609 out of 1120) were receiving concomitant corticosteroids, 355 (31.7%) out of 1120 were receiving concomitant mycophenolate mofetil and 340 (30.3%) out of 1120 were receiving another immunosuppressive/modulatory therapy. Radiological progression of ILD combined with worsening respiratory symptoms was the most common reason for the diagnosis of PF-ILD.CONCLUSION: We have demonstrated the use of nintedanib for the treatment of PF-ILD across a broad range of underlying conditions. Nintedanib is frequently co-prescribed alongside immunosuppressive and immunomodulatory therapy. The use of nintedanib for the treatment of PF-ILD has demonstrated acceptable tolerability in a real-world setting.
U2 - 10.1183/23120541.00529-2023
DO - 10.1183/23120541.00529-2023
M3 - Article (Academic Journal)
C2 - 38226064
SN - 2312-0541
VL - 10
JO - ERJ Open Research
JF - ERJ Open Research
IS - 1
M1 - 00529-2023
ER -